VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 1.6 %

NASDAQ:VBIV opened at $0.60 on Friday. The stock has a market capitalization of $17.04 million, a PE ratio of -0.05 and a beta of 1.93. The firm’s 50 day moving average is $0.61 and its 200 day moving average is $0.61. VBI Vaccines has a 12 month low of $0.45 and a 12 month high of $3.47.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.